Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy
Status:
Completed
Trial end date:
2017-11-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of inotersen given for 65
weeks in participants with Familial Amyloid Polyneuropathy (FAP).